Regulators Keep Rare Diseases Open For Business

 
• By David Wild
  
Economics of Disease
At a cost 10 times that of mass market illnesses, there is a strong imperative to keep incentivizing rare drug development • Source: Shutterstock
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Innovation

More from In Vivo